>>11737350 PB

>>11737361 PB

>What the WikiLeaks document dump tells us about the CIA's Frankfurt base

https:// wikileaks.org/hackingteam/emails/emailid/376658

difficult to see how this newsletter really reads with the formatting fucked up

think the view details separates the sections

Avere offers storage solutions that allow enterprises to leverage public and private cloud storage resources. The company has now raised $72 million in equity since its founding. It was valued at $146.5 million when it raised its $20 million Series C round in 2012.Avere Systems Database Software SaaS

Pittsburgh, PA $20 million Series D VIEW DETAILS InvestorsWestern Digital Capital (lead)Lightspeed Venture PartnersMenlo VenturesNorwest Venture PartnersTenaya Capital Scytl Elects for $20M in Funding SHARE: Scytl, a developer of an e-election management platform,''' has raised $20 million from SAP Ventures that will be used to continue R&D efforts and strategic growth. The company's full end-to-end platform covers processes from election planning and voter registration to online voting and reporting. It has raised $60 million so far in 2014, grabbing a $40 million round led by Vulcan Capital in April.Scytl Application Software SaaS

Barcelona, Spain $20 million Late Stage VC ''' VIEW DETAILS InvestorSAP Ventures Jobandtalent Raisesandcloses $14M Series A Round SHARE: Jobandtalent is a recruiting platform that matches professionals with relevant job opportunities using a linguistics-based algorithm, helping jobseekers to find opportunities they may otherwise miss.Jobandtalent Human Capital Services SaaS

>>11737533

>>11737533

https:// wikileaks.org/hackingteam/emails/emailid/379543

Ensure your profile is correctly represented to the thousands of people in the private equity and venture capital industry using the PitchBook Platform today, and get full credit in our upcoming reports. Request to review and update your PitchBook Profile by clicking below.

Click here to request your profile

Today's HeadlinesThe Daily Benchmark

2005 Vintage U.S. VC Funds

Completed VC Financings

Scytl Not Short on Election Funds

Rebiotix Pix Up $25M Series B

Cold Genesys Secures $13.57M in Series A Funds

Destiny Pharma Bags £2.8M

FlexWage Grabs $3.5M Advance

Kohler GoesFull Lightspeed Ahead

The Daily Benchmark2005 Vintage U.S. VC Funds SHARE: $500 million - $1 billion 7 Funds in BenchmarkMedian IRR: 6.04%Top Quartile IRR Hurdle Rate: 7.24%Median TVPI: 1.30xMedian DPI: 0.28x Select Top Performers (based on net IRR)Austin Ventures IXClarus Life Sciences IColumbia Capital Equity Partners IV Benchmark, Peer Group & Returns Data on 20,000 Funds

PitchBook, setting a higher bar for performance benchmarkingCompleted VC FinancingsScytl Not Short on Election Funds SHARE:Scytl, a provider of electronic voting solutions, has closed its latest funding round on $104 million after receiving an additional $44 million from Vy Capital, Adams Street Partners and Industry Ventures. The company initially raised funds for the round in April of this year when it received $40 million from Vulcan Capital; it then grabbed $20 million from __SAP Ventures __in July. Scytl has now raised over $116 million in equity financings.

'''Scytl's end-to-end platform helps manage pre-election finances, planning and voter registration, as well as election-day voting, election-night reporting and more. __The company became profitable in 2006 and since then has grown its revenues at an average of 70% per year, __operating from offices in 15 cities and serving customers in over 35 countries.Scytl Automation/Workflow Software SaaS

Barcelona, Spain $104 million '''Late Stage VC VIEW DETAILS InvestorsAdams Street PartnersIndustry VenturesSAP VenturesVulcan CapitalVy Capital Rebiotix Pix Up $25M Series B SHARE: Biotech firm Rebiotix has raised $25 million in Series B funding, bringing total capital raised since its founding in 2011 to $30 million. The company develops treatments for gastrointestinal diseases by harnessing the power of the human microbiome, restoring healthy gut flora through the transplantation of live microorganisms. Rebiotix will use the additional funds to support clinical research to advance its lead product, RBX2660, towards commercialization; for research and development on next-generation therapeutic products; for potential new treatment indications; and for general working capital. Rebiotix is currently working with the U.S. Food and Drug Administration to finalize plans for additional clinical studies needed to achieve regulatory approval for RBX2660.Rebiotix Biotechnology Life Sciences

Roseville, MN $25 million Series B VIEW DETAILS Cold Genesys Secures $13.57

>>11737454

>>11737454

I like this double meaning anon.